Jaehyup Kim

Aug 12, 2024 | digitalcommons.library.tmc.edu | Ryan Huang |Xiaoye Liu |Jaehyup Kim |Hui Deng

AbstractThe existing T cell-centered immune checkpoint blockade therapies have been successful in treating some but not all patients with cancer. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSC), that inhibit antitumor immunity and support multiple steps of tumor development are recognized as one of the major obstacles in cancer treatment.